200 1st Street SW
873 articles about Mayo Clinic
While GLP-1 drugs have exploded in popularity, they don’t work for everyone, and experts say phenotyping based on a greater understanding of the disease is the future of obesity treatment.
SimBioSys and Mayo Clinic Enter Strategic Collaboration to Advance AI-powered Digital Precision Medicine Platform for Cancer Patients
SimBioSys announced today it has entered into a strategic collaboration agreement with Mayo Clinic for the development of novel digital precision medicine solutions for breast cancer patients.
Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix® Infusion System
Fresenius Kabi announced it has signed a multiyear agreement under which the Mayo Clinic is expected to purchase 10,000 Ivenix® large-volume infusion pumps for its hospitals and clinics in Minnesota, Arizona and Florida.
Mayo Clinic Laboratories and Progentec® collaborate to bring advanced biomarker testing services to patients with autoimmune diseases
Mayo Clinic Laboratories and Progentec Diagnostics announced a strategic collaboration to bring Progentec's suite of proprietary biomarker blood tests for the proactive management of autoimmune diseases to market.
BioSig’s New PURE EP™ Subscription Model Adopted by Mayo Clinic-Phoenix for World-Class Cardiac Care
BioSig Technologies, Inc. announced that Mayo Clinic-Phoenix has upgraded to the Platform’s subscription model to gain immediate access to the Company’s latest technological advancements in cardiac arrhythmia identification.
Clarix Imaging®, a pioneering force in surgical oncology, proudly announces a collaboration with Mayo Clinic to catalyze new surgical advancements using Clarix Imaging’s proprietary and patented volumetric specimen imaging hardware and software technology.
Mayo Clinic and Oxford Nanopore announce collaboration to advance precision medicine for cancer and genetic disorders
Mayo Clinic and Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, unveiled a multi-year joint development collaboration to develop new clinical tests for diseases and improve patient care.
Perimeter Medical Imaging AI Announces Patient Randomization Underway at Clinical Trial Site at Mayo Clinic in Florida
Perimeter Medical Imaging AI, Inc. announced that patient randomization is underway at Mayo Clinic in Florida, the most recent clinical site to be initiated as part of an ongoing multi-center, randomized two-arm pivotal clinical trial evaluating the investigational Perimeter B-Series OCT combined with its proprietary ImgAssist AI software.
Anumana, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for ECG-AI LEF, a breakthrough artificial intelligence (AI)-powered medical device to detect low ejection fraction (LEF) in patients at risk of heart failure.
AccuLine Announces Know-How License Agreement with Mayo Clinic to Advance Early Detection of Heart Attacks
AccuLine, a digital health startup company, has announced a collaboration with Mayo Clinic through a know-how license agreement for the advancement of CORA, AccuLine's novel solution designed for the early detection of coronary artery disease.
Biostage, Inc. today announced that it officially activated the site with Mayo Clinic for its clinical trial as to severe esophageal disease, being its first clinical trial in the United States.
Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome
Aditxt®, Inc. today announces that its subsidiary Adimune™, Inc. (“Adimune”), has signed a clinical trial agreement with Mayo Clinic to advance clinical studies targeting autoimmune diseases.
Mayo Clinic Collaborates with Naveris to Advance Precision Medicine in HPV-driven Head and Neck Cancer with NavDx in DART 2.0 Clinical Trial
Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the launch of the DART 2.0 prospective clinical trial (NCT05541016) by Mayo Clinic.
Eclipse and Mayo Clinic announced the creation and seed funding of Nucleus RadioPharma, a new company built to ensure cancer patients can access potentially life-saving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain of these promising new therapies.
Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting
Daxor Corporation, the global leader in blood volume measurement technology, announces new data from the Mayo Clinic in Rochester, NY validating the benefits of the Company’s BVA-100 blood test for patients with heart failure.
A cell and gene therapy accelerator formed by Mayo Clinic, Hibiscus BioVentures and Innoforce is officially up and running, the partners announced this week.
Genomadix today announced it has entered into a know-how license agreement and stock purchase agreement with Mayo Clinic to advance its point of care molecular analyzer technology.
Metabolon , Inc. today announced a joint development agreement with Mayo Clinic to develop novel metabolomic biomarker diagnostic tests.
A recent study found that over a span of ten years, the FDA approved cancer drugs approximately eight months earlier than the same drugs were greenlit by the European Commission (EC).
Elysium Health™ Announces Research at Mayo Clinic to Study Associations Between NAD+ Levels and Senescent Cell Burden and Develop Epigenetic Measures of Cellular Senescence
Elysium Health, Inc.™, a leading life sciences company focused on aging research, today announced the initiation of research at Mayo Clinic to study associations between circulating nicotinamide adenine dinucleotide (NAD+) levels in healthy adults and senescent cell burden, and to develop novel epigenetic measures of cellular senescence.